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Abstract : Purpose : To investigate whether or not the physiological brain and liver FDG uptake are decreased in 
patients with highly accelerated glycolysis lesions. Methods : We retrospectively analyzed 51 patients with malig-
nant lymphoma. We compared the FDG uptake in the brain and liver of the patients with that in a control group. 
In 24 patients with a complete response (CR) or partial response (PR) to treatment, we compared the brain and 
liver uptake before and after treatment. Results : The maximum standardized uptake value (SUVmax) and total 
glycolytic volume (TGV) of the brain as well as the SUVmax and mean standardized uptake value (SUVmean) of 
the liver in malignant lymphoma patients were 13.1 ± 2.3, 7386.3 ± 1918.4, 3.2 ± 0.5, and 2.3 ± 0.4, respectively ; in 
the control group, these values were 14.9 ± 2.4, 8566.2 ± 1659.5, 3.4 ± 0.4, and 2.5 ± 0.3, respectively. The SUVmax 
and TGV of the brain and the SUVmean of the liver in malignant lymphoma patients were significantly lower 
than the control group. The SUVmax and TGV of the brain after treatment were significantly higher than before 
treatment. Both the SUVmax and SUVmean of liver after treatment were higher than before treatment, but not 
significant. Conclusion : A decreased physiological brain and liver FDG uptake is caused by highly accelerated 
lesion glycolysis. J. Med. Invest. 68 : 181-185, February, 2021
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INTRODUCTION
 
[18F] fluoro-2-deoxyglucose (FDG) positron emission tomog-
raphy / computed tomography (PET / CT) has been extensively 
utilized as a useful, non-invasive diagnostic imaging modality 
for evaluating a variety of neoplastic diseases (1-3). In the field 
of oncology, not only the visual assessment of the FDG uptake in 
tumor, the quantitative assessment of the FDG uptake in tumor 
lesions using the standardized uptake value (SUV) has gener-
ally been practiced (4, 5). Specifically, for malignant lymphoma, 
the liver and the blood pool of the mediastinum are used as a 
reference when assessing the tumor uptake (6-8).
However, the brain uptake is reportedly decreased in patients 
with large tumors with a high FDG uptake, such as malignant 
lymphoma and undifferentiated carcinoma (9-12). Furthermore, 
in the daily clinical course, the liver uptake may also seem to be 
decreased in patients with high-FDG-uptake tumors. 
The purpose of the present study was to determine whether or 
not the brain and liver uptake in patients with high-FDG-uptake 
tumors is decreased compared to patients with no tumors show-
ing an FDG uptake as a control. Considering the fact that the 
liver FDG uptake is frequently used for the reference region to 
evaluate tumor activity, it is meaningful to correctly comprehend 
the factors that affect the liver uptake. 
MATERIALS AND METHODS
Patients
We retrospectively analyzed 51 patients with malignant 
lymphoma. We compared the brain and liver uptake of these 51 
patients with those of another 51 patients in the control group. 
Among 24 patients with a complete response (CR) or partial 
response (PR) to treatment, we compared the brain and liver up-
take before and after treatment. In addition, the liver uptake in 
these 24 patients was compared before and after treatment spe-
cifically among those in whom the liver uptake before treatment 
were lower than the median of the control group.
This retrospective study was approved by the Ethics Commit-
tee of Tokushima University Hospital (approval number : 3210). 
The need for written informed consent from the patients was 
waived by the Ethics Committee of Tokushima University 
Hospital.
• Malignant lymphoma group
Fifty-one patients (male, n = 27 ; female, n = 24 ; mean age 
64.6 years) in whom the uptake of FDG was detected in ma-
lignant lymphoma lesions with total lesion glycolysis (TLG) 
> 100 on PET / CT from April 2015 to January 2018 and in 
whom Hodgkin’s or non-Hodgkin’s lymphoma was histologically 
confirmed. All patients in the malignant lymphoma group un-
derwent FDG PET / CT examination before any treatment for 
malignant lymphoma. None of them received treatment, such 
as chemotherapy, for at least 3 months before PET / CT examina-
tion. The patients had no history of cerebrovascular disorders, 
brain tumors, liver disorders, liver invasion, or liver tumors. We 
excluded cases of hepatic steatosis (less than 40 Hounsfield units 
on CT). Patients whose blood sugar was less than 140 mg / dl be-
fore FDG injection were included. Patients with diabetes melli-
tus were included if their blood glucose level is within this range. 
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The malignant lymphoma and control groups each included four 
cases of type 2 diabetes mellitus.
• Control group
Fifty-one age-, gender-, and body weight-matched patients who 
underwent FDG PET / CT from January 2018 to April 2018 were 
enrolled as the control group (12, 13). The control patients had 
already been treated for cancer and had no relapse for at least 
six months without treatment. They had no history of cerebro-
vascular disorders, brain tumors, liver disorders, liver invasion, 
or liver tumors. We excluded cases of hepatic steatosis (less than 
40 Hounsfield units on CT). Patients whose blood sugar was less 
than 140 mg / dl before FDG injection were included.
 
Evaluating the FDG uptake of malignant lymphoma and in the brain 
and liver of the two groups
A physician specializing in nuclear medicine evaluated the 
FDG PET / CT images. The volume of the tumor with an SUV 
≥ 2.5 was determined as the metabolic tumor volume (MTV) (ml) 
(14, 15). The TLG of patients with malignant lymphoma was cal-
culated by establishing volumes of interest (VOI) for all abnor-
mal uptakes of malignant lymphoma lesions on an image viewer 
(AW server 2.0 ; GE Healthcare). The maximum SUV (SUVmax) 
and total glycolytic volume (TGV) of the brain were calculated by 
setting the VOI in the whole brain of the two groups. The SUVmax 
and mean SUV (SUVmean) of the liver were also calculated by 
setting the region of interest (ROI) in the liver of the two groups 
automatically using the function of AW server 2.0.
Statistical analyses
The parameters were expressed as the mean ± standard de-
viation. The homogeneity of variance was tested by the Levene’s 
test. The normality of the distribution of the variables was tested 
by the Kolmogolov-Smirnov test. Student’s t-test (normal distri-
bution) or Welch’s t-test (non-normal distribution) was applied 
to evaluate differences in the variables of the parameters. The 
relationships between the liver and brain uptake and the tumor 
lesion uptake level were quantified using Spearman’s correla-
tion analysis. The SPSS Statistics software program (version 
24 ; IBM, Chicago, IL, USA) was used to perform the statistical 
analyses. A p value of less than 0.05 was considered statistically 
significant.
RESULTS
The details of the 51 cases of malignant lymphoma are as fol-
lows : 21 diffuse large B-cell lymphoma, 17 follicular lymphoma, 
5 Hodgkin’s lymphoma, 2 extra-nodal marginal zone lymphoma 
of mucosa-associated lymphoid tissue, 1 Burkitt lymphoma, 
1 anaplastic large cell lymphoma, 1 T-cell lymphoma, and 3 
malignant lymphoma of unknown classification. The TLG of 
the malignant lymphoma group was 2383.0 ± 3866.6 (range 
112.8–21880.1). The therapeutic evaluation was as follows : 20 
cases with CR, 4 cases with PR, and 1 case with progressive dis-
ease (PD) in 25 patients who underwent follow-up FDG PET / CT. 
The clinical characteristics of the study groups are shown in 
Table 1. None of the parameters of age, gender, body weight, 
blood glucose, and FDG dose in the two groups was statistically 
significant.
A comparison of the brain and liver uptake in the two study 
groups is shown in Table 2. The SUVmax and TGV of the brain 
and the SUVmax and SUVmean of the liver in patients with malig-
nant lymphoma were 13.1 ± 2.3, 7386.3 ± 1918.4, 3.2 ± 0.5, and 
2.3 ± 0.4, respectively ; in the control group, these values were 
14.9 ± 2.4, 8566.2 ± 1659.5, 3.4 ± 0.4, and 2.5 ± 0.3, respectively. 
The SUVmax and TGV of the brain and the SUVmean of the liver of 
the malignant lymphoma patients were significantly lower than 
in the control group (p = 0.0003, 0.001, and 0.017, respectively). 
The SUVmax of the liver of the malignant lymphoma patients was 
lower than in the control group, but not to a significant degree 
(p = 0.055). There were no statistically significant correlations 
between TLG and liver SUVmax (r = -0.060, p = 0.678) and liver 
SUVmean (r = -0.191, p = 0.179). There were no statistically signifi-
cant correlations between the TLG and brain SUVmax (r = -0.064, 
p = 0.654) or brain TGV (r = -0.114, p = 0.427).
A comparison of the brain and liver uptake before and after 
treatment in 24 CR and PR cases is shown in Table 3. The 
SUVmax and TGV of the brain and the SUVmax and SUVmean of 
the liver in patients with malignant lymphoma were 13.2 ± 1.8, 
7545.1 ± 1727.8, 3.2 ± 0.4, 2.3 ± 0.3, respectively, before treat-
ment and 14.6 ± 2.3, 8459.6 ± 1834.6, 3.3 ± 0.3, 2.4 ± 0.3, respec-
tively, after treatment. The SUVmax and TGV of the brain of 24 
malignant lymphoma patients after treatment with CR and PR 
were significantly higher than before treatment (p = 0.015 and 
0.027, respectively). Both the SUVmax and SUVmean of liver of 24 
patients after treatment were higher than before treatment, but 
not to a significant degree (p = 0.446 and 0.237, respectively). In 
the 24 cases, an evaluation limited to cases in which the liver 
uptake (SUVmax, SUVmean) before treatment was lower than the 
median of the control group (SUVmax : n = 13, SUVmean : n = 16) 
showed that the liver SUVmax after treatment in 13 cases was 
higher than that before treatment, but not to a significant degree 







Age (years) 64.6 ± 13.6 64.4 ± 12.6 p = 0.952
Gender p = 1.000
   Female 24 24
   Male 27 27
Weight (kg) 58.5 ± 9.2 58.1 ± 12.0 p = 0.861
Blood glucose (mg / dl) 102.9 ± 14.5 103.8 ± 10.4 p = 0.707
FDG (MBq) 179.1 ± 31.1 181.4 ± 39.4 p = 0.743
Data were represented as mean ± standard deviation. A p value 
less than 0.05 was considered statistically significant.
FDG, fluorodeoxyglucose










   SUVmax 13.1 ± 2.3 14.9 ± 2.4 p = 0.0003
   TGV 7386.3 ± 1918.4 8566.2 ± 1659.5 p = 0.001
Liver
   SUVmax 3.2 ± 0.5 3.4 ± 0.4 p = 0.055
   SUVmean 2.3 ± 0.4 2.5 ± 0.3 p = 0.017
Data are presented as the mean ± standard deviation. A p value 
less than 0.05 was considered statistically significant. 
SUVmax, maximum standardized uptake value ; SUVmean, mean 
standardized uptake value ; TGV, total glycolytic volume
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(p = 0.051), and the liver SUVmean after treatment in 16 cases 
was significantly higher than that before treatment (p = 0.005) 
(Table 4). 
Fig. 1 shows PET / CT images of a case showing a decreased 
brain and liver uptake with a high FDG uptake in malignant 
lymphoma lesions. Fig. 2 shows PET / CT images of a control 
case. Fig. 3A shows the FDG PET / CT images of a case which 
showed a reduced brain and liver uptake with a high uptake to 
the tumor lesions of diffuse large B-cell lymphoma. Thereafter, 
this case showed an increased brain and liver uptake with a 
decreasing uptake of the tumor after chemotherapy (Fig. 3B).
 
DISCUSSION
The uptake of FDG in the brain of patients with malignant 
lymphoma was significantly lower than that in the control group. 
However, no significant correlation was found between the brain 
uptake and TLG of lymphoma in this study. A previous report 
described a statistically significant negative correlation between 
TLG of lymphoma and the brain FDG uptake in patients with 
non-Hodgkin’s lymphoma (12). Previous papers have also val-
idated the phenomenon of a decreased brain FDG uptake due 
to a substantial tumor uptake (12, 16), implying that there is 
competition between the tumor and brain to capture FDG (12).
Several factors that may decrease the brain uptake have 
been reported. The extent of the brain uptake depends on the 
blood glucose level. Previous authors have reported a significant 
impact of glycemia on the FDG uptake in the brain cortex, as 
patients with higher blood glucose levels presented progressively 
lower cortical SUVs (17-20). Exercise also reduces the brain FDG 
uptake (21, 22). Lactate is a substrate other than glucose that is 
reportedly utilized by the brain during high-intensity exercise 
in order to compensate for the increased energy requirement to 
maintain neuronal activity ; this activity may reduce the brain 
uptake. For this reason, patients with hyperglycemia (blood 
glucose levels above 140 mg / dl) were excluded from our study. 
We also urged all patients to avoid intense exercise before the 
PET / CT examination.
In the present study, we showed that the brain uptake after 
treatment in CR and PR cases was significantly higher than 
that before treatment. This result suggests that the distribution 
Table 3.　The brain and liver uptake before and after treatment in 
24 CR and PR cases
Parameter Pre-treatment Post-treatment p value
Brain
   SUVmax 13.2 ± 1.8 14.6 ± 2.3 p = 0.015
   TGV 7545.1 ± 1727.8 8459.6 ± 1834.6 p = 0.027
Liver
   SUVmax 3.2 ± 0.4 3.3 ± 0.3 p = 0.446
   SUVmean 2.3 ± 0.3 2.4 ± 0.3 p = 0.237
Data are presented as the mean ± standard deviation. A p value 
less than 0.05 was considered statistically significant. 
CR, complete response ; PR, partial response ; SUVmax, maximum 
standardized uptake value ; SUVmean, mean standardized uptake 
value ; TGV, total glycolytic volume
Table 4.　The CR / PR cases in which liver uptake pre-treatment is 
less than median of control group
Parameter Pre-treatment Post-treatment p value
Liver
   SUVmax (n = 13) 2.9 ± 0.3 3.2 ± 0.3 p = 0.051
   SUVmean(n = 16) 2.2 ± 0.3 2.4 ± 0.2 p = 0.005
Data are presented as the mean ± standard deviation. A p value 
less than 0.05 was considered statistically significant.
CR, complete response ; PR, partial response ; SUVmax, maximum 
standardized uptake value ; SUVmean, mean standardized uptake 
value
Fig 1.　FDG PET / CT images of representative case showing brain 
and liver uptake decrease with high tumor uptake. The tumor 
was diffuse large B-cell lymphoma (DLBCL). Maximum intensity 
projection of FDG PET (a), PET / CT fusion image of brain (b), PET / CT 
fusion image of liver (c) of a 70-year-old male. Each parameter 
follows ; SUVmax of 2.9, SUVmean of 2.2 in liver, SUVmax of 11.4, 
TGV of 6958.0 in brain, SUVmax of 31.3, TLG of 3450.4, MTV of 
329.6 in DLBCL lesions.
Fig 2.　FDG PET / CT images of representative case of control group. 
Maximum intensity projection of FDG PET (a), PET / CT fusion image 
of brain (b), PET / CT fusion image of liver (c) of a 60-year-old male. 
Each parameter follows ; SUVmax of 3.4, SUVmean of 2.6 in liver, 
SUVmax of 14.0, TGV of 8058.0 in brain.
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to the brain increased after treatment because the uptake in the 
tumor was reduced, supporting the notion that there is competi-
tion between the tumor and brain in capturing FDG.
The FDG uptake (SUVmean) of the liver in patients with malig-
nant lymphoma was also significantly lower than that in control 
patients. However, while the SUVmax of the liver in patients with 
malignant lymphoma was lower than that in control patients as 
well, no significant differences were seen. A previous paper vali-
dated the phenomenon of a decreased liver FDG uptake due to a 
substantial tumor uptake (16). The decrease in the liver FDG up-
take in the presence of tumors with a large amount of FDG accu-
mulated is suspected to be due to competition between the tumor 
and the liver, as reported for the decreased brain uptake in the 
presence of tumors with a large amount of FDG accumulated. 
Since some of the FDG that should intrinsically accumulate in 
the liver is taken up by the tumor instead, the liver’s allocation is 
consequently decreased.
Several factors that may influence the liver uptake have been 
reported so far. Abele et al. reported no association between the 
liver attenuation and the FDG uptake measured in terms of the 
SUVmean (23). However, Keramida et al. reported that the liver 
FDG uptake was increased in cases of hepatic steatosis (CT 
density of liver < 40 HU) (24). The authors suggested that this 
likely results from the uptake in inflammatory cells being super-
imposed on the hepatocyte uptake. Liu et al. also reported that 
a mild and moderate degree of fatty liver had a positive effect 
on the liver FDG uptake, whereas a severe degree of fatty liver 
negatively affected the FDG uptake (25). In the present study, we 
excluded patients with hepatic steatosis.
Keramida et al. additionally reported that the fasting hepatic 
FDG uptake was higher in men than in women (26). However, 
Lin reported that there was no statistically significant relation-
ship between gender and the SUVmax or SUVmean of the liver (27). 
Since the uptake of the liver may be affected by gender, the ratio 
between men and women was set to be the same for both groups 
in the present study. Lin et al. further reported that age had a sig-
nificant and positive impact on both the SUVmax and SUVmean of 
the liver on FDG PET (27). Viglianti et al. reported that increased 
blood glucose levels had a mild effect on the liver SUV (19). Since 
the uptake of the liver may be affected by age and blood glucose 
levels, the average age and blood glucose levels were set to be 
roughly the same in both groups in the present study.
In the present study, we showed that the liver uptake after 
treatment in CR and PR cases was higher than that before 
treatment, although there was no significant difference. In cases 
in which the liver uptake was low before treatment, the value 
(SUVmean) after treatment in CR and PR was significantly higher 
than that before treatment. This result suggests that, similar 
to the distribution to the brain, the distribution to the liver was 
increased due to a decreased tumor uptake.
The present study has some limitations. First, there was se-
lection bias due to the retrospective nature of the study. Second, 
this study may have included hidden liver lesions within the 
ROI. Patients with locally identifiable abnormalities in the liver 
were excluded from the analysis but may also have had liver 
hemangiomas, small liver cysts, vascular abnormalities, unde-
tectable hepatocellular carcinoma or liver metastasis with a low 
FDG uptake and so on. Finally, it was reported that the body 
mass index (BMI) affects the liver FDG uptake (25) ; however, as 
this was a retrospective study, it was not possible to compute the 
BMI because the height data were unavailable. As such, there 
may have been a significant difference in the BMI between the 
two groups, although there was no significant difference in the 
body weight between the two groups.
However, despite these limitations, our present findings sug-
gest that the decrease in the physiological uptake of the brain 
might be caused by a high uptake in malignant lymphoma 
lesions. Our study also suggested that a decrease in the physio-
logical uptake in the liver may also be caused by a high uptake 
in malignant lymphoma lesions. Furthermore, the present study 
is the first report to confirm that the uptake in the brain and 
liver, which had been reduced due to a high uptake in the ma-
lignant lymphoma lesions, was recovered by the uptake of the 
tumor decreasing after treatment. The FDG uptake is graded in 
relation to the reference regions of the normal mediastinum and 
liver. The Deauville criteria and the Deauville five-point scale, 
in which the normal mediastinum and liver are used for the 
reference regions, are used to evaluate the activity of malignant 
Fig 3.　The increase and recovery of brain and liver uptake with decreasing tumor uptake after chemotherapy. FDG PET / CT images of the 
case in which had showed decreased brain and liver uptake with high uptake in the lesions of tumor of DLBCL (A), which showed the uptake 
of brain and liver increase and recovery with decreasing uptake of tumor after chemotherapy (B). Maximum intensity projection of FDG 
PET (a), PET / CT fusion image of brain (b), PET / CT fusion image of liver (c) of a 40-year-old female. A : Each parameter follows ; SUVmax of 
2.9, SUVmean of 2.2 in liver, SUVmax of 12.3, TGV of 6896.1 in brain. B : Each parameter follows; SUVmax of 3.0, SUVmean of 2.4 in liver, 
SUVmax of 14.7, TGV of 8054.2 in brain.
185The Journal of Medical Investigation   Vol. 68  February  2021
lymphoma (6-8). Identifying factors that affect the uptake of the 
normal liver therefore seems to be crucial.
CONCLUSIONS
In malignant lymphoma patients with a high FDG uptake 
in the tumors, the uptake in the liver and brain is decreased. 
Furthermore, the uptake in these organs tends to recover with 
the decreased uptake in the tumor after treatment. Highly accel-
erated lesion glycolysis in malignant lymphoma seems to induce 
a decreased physiological brain and liver FDG uptake. Some of 
the FDG that should accumulate in the brain and liver is taken 
up by the tumor, resulting in a decreased allocation to the brain 
and liver. 
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